Zydus Cadila has received the final approval from the USFDA to market Mesalamine Suppositories for rectal use, (US RLD – Canasa) 1000 mg. The drug is used to treat ulcerative proctitis, a type of bowel disease. It is an aminosalicylate anti-inflammatory drug and believed to work by blocking the production of certain natural chemicals that may cause pain and swelling. This will be manufactured at the group’s Topical manufacturing facility at Ahmedabad.
The group now has 280 approvals and has so far filed over 386 ANDAs since the commencement of the filing process in FY 2003-04.
Shares of CADILA HEALTHCARE LTD. was last trading in BSE at Rs.271.2 as compared to the previous close of Rs. 274.6. The total number of shares traded during the day was 22667 in over 880 trades.
The stock hit an intraday high of Rs. 276.25 and intraday low of 270.55. The net turnover during the day was Rs. 6178510.-Equity Bulls